Health Information Management

Q&A: Why is a drug being removed from our CDM?

APCs Insider, September 26, 2014

Want to receive articles like this one in your inbox? Subscribe to APCs Insider!

Q: Our charge description master (CDM) manager wants to remove the code for denileukin from our CDM, as the status is changing. Why is this happening?
 
A: CMS is changing the status indicator for the HCPCS code for denileukin (J9160), effective October 1. The status indicators for J9160 and J9300 (gemtuzumab ozogamicin) are changing from K (non pass-through drugs and biologicals, and blood and blood products) to E (not paid by Medicare when submitted on outpatient claims) because the products are no longer marketed.
 
CMS noted the availability in MLN Matters® article 8880, the October 2014 update for ambulatory surgery centers (the transmittal for the October OPPS update for hospital providers is available in a separate file).
 
Editor’s note: Denise Williams, RN, CPC-H, seniorvice president of revenue integrity services at Health Revenue Assurance Associates, Inc., in Plantation, Florida, answered this question.



Want to receive articles like this one in your inbox? Subscribe to APCs Insider!

    Briefings on APCs
  • Briefings on APCs

    Worried about the complexities of the new rules under OPPS and APCs? Briefings on APCs helps you understand the new rules...

  • HIM Briefings

    Guiding Health Information Management professionals through the continuously changing field of medical records and toward a...

  • Briefings on Coding Compliance Strategies

    Submitting improper Medicare documentation can lead to denial of fees, payback, fines, and increased diligence from payers...

  • Briefings on HIPAA

    How can you minimize the impact of HIPAA? Subscribe to Briefings on HIPAA, your health information management resource for...

  • APCs Insider

    This HTML-based e-mail newsletter provides weekly tips and advice on the new ambulatory payment classifications regulations...

Most Popular